Cargando…
Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
INTRODUCTION: Antidepressant drugs are effective therapies for major depressive disorder; however, they are frequently associated with side effects. Although there is some evidence for a relationship between genetic variation and side effects, little is known regarding the role of dynamic molecular...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093997/ https://www.ncbi.nlm.nih.gov/pubmed/31819986 http://dx.doi.org/10.1093/ijnp/pyz066 |
_version_ | 1783510386397413376 |
---|---|
author | Yrondi, Antoine Fiori, Laura M Frey, Benicio N Lam, Raymond W MacQueen, Glenda M Milev, Roumen Müller, Daniel J Foster, Jane A Kennedy, Sidney H Turecki, Gustavo |
author_facet | Yrondi, Antoine Fiori, Laura M Frey, Benicio N Lam, Raymond W MacQueen, Glenda M Milev, Roumen Müller, Daniel J Foster, Jane A Kennedy, Sidney H Turecki, Gustavo |
author_sort | Yrondi, Antoine |
collection | PubMed |
description | INTRODUCTION: Antidepressant drugs are effective therapies for major depressive disorder; however, they are frequently associated with side effects. Although there is some evidence for a relationship between genetic variation and side effects, little is known regarding the role of dynamic molecular factors as moderators of side effects. The aim of this study was to assess microRNA (miRNA) changes associated with side effects during escitalopram treatment and their downstream effects on target gene expression. METHODS: A total 160 patients with major depressive disorder from the CAN-BIND-1 cohort were included. Side effects were assessed with the Toronto Side Effect Scale after 2 weeks of treatment with escitalopram. We assessed the relationship between side effects and changes in peripheral expression of miRNAs between baseline and week 2. For miRNA whose expression changed, we used target prediction algorithms to identify putative messenger RNA (mRNA) targets and assessed their expression. RESULTS: Nausea was experienced by 42.5% of patients. We identified 45 miRNAs whose expression changed on initiation of escitalopram treatment, of which 10 displayed a negative association with intensity of nausea (miR15b-5p, miR17-5p, miR20a-5p, miR20b-5p, miR103a-3p, miR103b, miR106a-5p, miR182-5p, miR185-5p, and miR660-5p). Additionally, we found negative associations between 4 microRNAs (miR20a-5p, miR106a-5p, miR185-5p, miR660-5p) and mRNA targets. The expression of the miR185-5p target, CAMK2δ was significantly decreased [log 2 mean = −0.048 (0.233)] between weeks 0 and 2 (P = .01)]. CONCLUSIONS: We identified an overexpression of miR185-5p during escitalopram treatment of major depressive disorder, which was negatively associated with intensity of nausea, and identified a potential mRNA target that may mediate this effect. |
format | Online Article Text |
id | pubmed-7093997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-70939972020-03-31 Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report Yrondi, Antoine Fiori, Laura M Frey, Benicio N Lam, Raymond W MacQueen, Glenda M Milev, Roumen Müller, Daniel J Foster, Jane A Kennedy, Sidney H Turecki, Gustavo Int J Neuropsychopharmacol Regular Research Articles INTRODUCTION: Antidepressant drugs are effective therapies for major depressive disorder; however, they are frequently associated with side effects. Although there is some evidence for a relationship between genetic variation and side effects, little is known regarding the role of dynamic molecular factors as moderators of side effects. The aim of this study was to assess microRNA (miRNA) changes associated with side effects during escitalopram treatment and their downstream effects on target gene expression. METHODS: A total 160 patients with major depressive disorder from the CAN-BIND-1 cohort were included. Side effects were assessed with the Toronto Side Effect Scale after 2 weeks of treatment with escitalopram. We assessed the relationship between side effects and changes in peripheral expression of miRNAs between baseline and week 2. For miRNA whose expression changed, we used target prediction algorithms to identify putative messenger RNA (mRNA) targets and assessed their expression. RESULTS: Nausea was experienced by 42.5% of patients. We identified 45 miRNAs whose expression changed on initiation of escitalopram treatment, of which 10 displayed a negative association with intensity of nausea (miR15b-5p, miR17-5p, miR20a-5p, miR20b-5p, miR103a-3p, miR103b, miR106a-5p, miR182-5p, miR185-5p, and miR660-5p). Additionally, we found negative associations between 4 microRNAs (miR20a-5p, miR106a-5p, miR185-5p, miR660-5p) and mRNA targets. The expression of the miR185-5p target, CAMK2δ was significantly decreased [log 2 mean = −0.048 (0.233)] between weeks 0 and 2 (P = .01)]. CONCLUSIONS: We identified an overexpression of miR185-5p during escitalopram treatment of major depressive disorder, which was negatively associated with intensity of nausea, and identified a potential mRNA target that may mediate this effect. Oxford University Press 2019-12-10 /pmc/articles/PMC7093997/ /pubmed/31819986 http://dx.doi.org/10.1093/ijnp/pyz066 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Regular Research Articles Yrondi, Antoine Fiori, Laura M Frey, Benicio N Lam, Raymond W MacQueen, Glenda M Milev, Roumen Müller, Daniel J Foster, Jane A Kennedy, Sidney H Turecki, Gustavo Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report |
title | Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report |
title_full | Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report |
title_fullStr | Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report |
title_full_unstemmed | Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report |
title_short | Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report |
title_sort | association between side effects and blood microrna expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a can-bind-1 report |
topic | Regular Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093997/ https://www.ncbi.nlm.nih.gov/pubmed/31819986 http://dx.doi.org/10.1093/ijnp/pyz066 |
work_keys_str_mv | AT yrondiantoine associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT fiorilauram associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT freybenicion associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT lamraymondw associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT macqueenglendam associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT milevroumen associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT mullerdanielj associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT fosterjanea associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT kennedysidneyh associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report AT tureckigustavo associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report |